Empagliflozin in Acute Myocardial Infarction Reduces No-Reflow and Preserves Cardiac Function by Preventing Endothelial Damage.

• Tác giả: Anna Agapaki, Ioanna Andreadou, Pierre Boucher, Yannis Dotsikas, Anastasios Georgoulis, Stéphane Germain, Dimitris Grigoriadis, Artemis G Hatzigeorgiou, Ignatios Ikonomidis, Lara S F Konijnenberg, Nikolaos Kostomitsopoulos, Ioannis V Kostopoulos, Carolien T A Kuster, Yannis Loukas, Tom T J Luiken, Marios Miliotis, Nikolaos Mylonas, Robin Nijveldt, Panagiota Efstathia Nikolaou, Nikolaos Orologas, Gaëtan Pallot, George Pavlidis, Michael Paul Pieper, Rona Roverts, Ourania Tsitsilonis, Vince P A van Reijmersdal, Niels van Royen, Coert J Zuurbier
• Ngôn ngữ: eng
• Ký hiệu phân loại: 553.453 Tin
• Thông tin xuất bản: United States : JACC. Basic to translational science , 2025
• Bộ sưu tập: NCBI
• ID: 171294

Tóm tắt

Empagliflozin treatment before acute myocardial infarction mainly targets the endothelial cell transcriptome. Empagliflozin treatment before and after myocardial infarction decreased no reflow and microvascular injury, leading to reduced infiltration of inflammatory cells, reduced infarct size, and improved cardiac function in mice. In diabetic patients receiving empagliflozin after myocardial infarction, perfused boundary region, flow-mediated dilation, and global longitudinal strain were improved.